154.26 0.00 (0.00%)
After hours: 4:30PM EDT
|Bid||152.00 x 200|
|Ask||161.78 x 100|
|Day's range||153.08 - 157.66|
|52-week range||128.58 - 163.75|
|PE ratio (TTM)||19.38|
|Earnings date||7 May 2018 - 11 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||182.43|
NEW YORK, March 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Jazz Pharmaceuticals (JAZZ) earnings and revenues miss estimates in Q4. However, the company posts a strong bottom and top-line guidance for 2018.
The Dublin-based company said it had profit of $3.79 per share. Earnings, adjusted for one-time gains and costs, were $2.95 per share. The results fell short of Wall Street expectations. The average estimate ...
In Q4, we expect investors' focus on Xyrem's performance, Jazz Pharmaceuticals' (JAZZ) lead product for excessive daytime sleepiness. Also, hopes will be pinned on the company's pipeline progress.
Valeant Pharmaceuticals (VRX) is a specialty pharmaceutical company involved in the development, manufacture, and marketing of branded, generic, branded generic as well as over the counter products. Of the seven analysts covering Valeant Pharmaceuticals in February 2018, two analysts have given the stock a “buy” or higher rating. Three analysts have given it a “hold” rating, and two analysts have given the stock a “sell” rating.
Shares of Concert Pharmaceuticals (CNCE) nosedive after the Patent Trial and Appeal Board decided not to grant a Post Grant Review petition in patent '335 dispute with Incyte.
In 3Q17, Jazz Pharmaceuticals’ (JAZZ) Erwinaze generated revenue of $49 million, which reflected a rise of ~14% on a year-over-year (or YoY) basis.
In 3Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenue of $303.9 million, which reflected a rise of ~6% on a YoY (year-over-year) basis.
In 3Q17, Jazz Pharmaceuticals generated revenue of $411.9 million, which reflected a ~10% rise on a year-over-year basis and a 4% rise on a quarter-over-quarter basis.
In December 2017, Jazz Pharmaceuticals (JAZZ) submitted a New Drug Application (or NDA) to the FDA for the approval of JZP-110.
Jazz submits a new drug application to the FDA for JZP-110 (solriamfetol) for treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.
Drugmakers are using a variety of strategies to extend the exclusivity period of their wares, keeping less expensive alternatives away from patients.
A medical charity that received hundreds of millions of dollars from pharmaceutical companies lost a crucial stamp of approval from the U.S. government, after allowing its donors improper influence over ...
Jazz Pharmaceuticals (JAZZ) earnings beat estimates while revenues miss the same in Q3. The company also cuts its guidance due to lower-than-expected sales from Xyrem.
Jazz Pharmaceuticals' (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q3, thanks to label expansion efforts. Also, other products look promising to lead to an earnings beat.
Genocea Biosciences (GNCA) was a big mover last session, as the company saw its shares rise almost 25% on the day amid huge volumes.